Mydecine Hits Milestone With New AI-Powered Program | Chief Science Officer Rob Roscow
Mydecine Innovations Group (NEO: MYCO)(OTCMKTS: MYCOF) is turning to artificial intelligence in its quest to develop the most effective psychedelic therapeutic drug offerings on the market today. It was announced this week that Mydecine had successfully developed a target-based model…